Combining Pre- and Postoperative Lymphocyte–C-Reactive Protein Ratios Can Better Predict Hepatocellular Carcinoma Prognosis After Partial Hepatectomy

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Ng KKC, Chok KSH, Chan ACY, et al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg. 2017;104(13):1775–1784. doi:10.1002/bjs.10677
   PubMed Web of Science ®Google Scholar
• Di Sandro S, Centonze L, Pinotti E, et al. Surgical and oncological outcomes of hepatic resection for BCLC-B hepatocellular carcinoma: a retrospective multicenter analysis among 474 consecutive cases. Updates Surg. 2019;71(2):285–293. doi:10.1007/s13304-019-00649-w
   PubMed Web of Science ®Google Scholar
• Chen LJ, Chang YJ, Chang YJ. Survival predictability between the American joint committee on cancer 8th edition staging system and the Barcelona clinic liver cancer classification in patients with hepatocellular carcinoma. Oncologist. 2021;26(3):e445–e453. doi:10.1002/onco.13535
   PubMed Web of Science ®Google Scholar
• Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19(3):222–232. doi:10.1038/s41590-018-0044-z
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503. doi:10.1016/S1470-2045(14)70263-3
   PubMed Web of Science ®Google Scholar
• Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol. 2015;12(10):584–596. doi:10.1038/nrclinonc.2015.105
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Mei J, Sun XQ, Lin WP, et al. Comparison of the prognostic value of inflammation-based scores in patients with hepatocellular carcinoma after anti-PD-1 therapy. J Inflamm Res. 2021;14:3879–3890. doi:10.2147/jir.S325600
   PubMed Web of Science ®Google Scholar
• Yang J, Bao Y, Chen W, Duan Y, Sun D. Nomogram based on systemic immune inflammation index and prognostic nutrition index predicts recurrence of hepatocellular carcinoma after surgery. Front Oncol. 2020;10:551668. doi:10.3389/fonc.2020.551668
   PubMed Web of Science ®Google Scholar
• Zheng J, Cai J, Li H, et al. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for hepatocellular carcinoma patients with various treatments: a meta-analysis and systematic review. Cell Physiol Biochem. 2017;44(3):967–981. doi:10.1159/000485396
   PubMedGoogle Scholar
• Song W, Tian C, Wang K, Zhang RJ, Zou SB. The pretreatment lymphocyte to monocyte ratio predicts clinical outcome for patients with hepatocellular carcinoma: a meta-analysis. Sci Rep. 2017;7(1):46601. doi:10.1038/srep46601
   PubMed Web of Science ®Google Scholar
• Ismael MN, Forde J, Milla E, Khan W, Cabrera R. Utility of inflammatory markers in predicting hepatocellular carcinoma survival after liver transplantation. Biomed Res Int. 2019;2019:7284040. doi:10.1155/2019/7284040
   PubMed Web of Science ®Google Scholar
• Zhang YF, Lu LH, Zhong C, Chen MS, Guo RP, Wang L. Prognostic value of the preoperative lymphocyte-c-reactive protein ratio in hepatocellular carcinoma patients treated with curative intent: a large-scale multicentre study. J Inflamm Res. 2021;14:2483–2495. doi:10.2147/jir.S311994
   PubMed Web of Science ®Google Scholar
• Yugawa K, Maeda T, Kinjo N, et al. Prognostic impact of lymphocyte-C-reactive protein ratio in patients who underwent surgical resection for hepatocellular carcinoma. J Gastrointest Surg. 2021;26(1):104–112. doi:10.1007/s11605-021-05085-z
   PubMed Web of Science ®Google Scholar
• Peng W, Li C, Wen TF, et al. Neutrophil to lymphocyte ratio changes predict small hepatocellular carcinoma survival. J Surg Res. 2014;192(2):402–408. doi:10.1016/j.jss.2014.05.078
   PubMed Web of Science ®Google Scholar
• Wu M, Yang S, Feng X, et al. Combining preoperative and postoperative inflammatory indicators can better predict the recurrence of hepatocellular carcinoma after partial hepatectomy. J Inflamm Res. 2021;14:3231–3245. doi:10.2147/jir.S316177
   PubMed Web of Science ®Google Scholar
• Li C, Wen TF, Yan LN, et al. Postoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio predicts the outcomes of hepatocellular carcinoma. J Surg Res. 2015;198(1):73–79. doi:10.1016/j.jss.2015.05.003
   PubMed Web of Science ®Google Scholar
• Li X, Montazeri SA, Paz-Fumagalli R, et al. Prognostic significance of neutrophil to lymphocyte ratio dynamics in patients with hepatocellular carcinoma treated with radioembolization using glass microspheres. Eur J Nucl Med Mol Imaging. 2021;48(8):2624–2634. doi:10.1007/s00259-020-05186-y
   PubMed Web of Science ®Google Scholar
• Jakubowska K, Koda M, Kisielewski W, Kańczuga-Koda L, Grudzińska M, Famulski W. Pre- and postoperative neutrophil and lymphocyte count and neutrophil-to-lymphocyte ratio in patients with colorectal cancer. Mol Clin Oncol. 2020;13(5):56. doi:10.3892/mco.2020.2126
   PubMed Web of Science ®Google Scholar
• Min KW, Kwon MJ, Kim DH, et al. Persistent elevation of postoperative neutrophil-to-lymphocyte ratio: a better predictor of survival in gastric cancer than elevated preoperative neutrophil-to-lymphocyte ratio. Sci Rep. 2017;7(1):13967. doi:10.1038/s41598-017-13969-x
   PubMed Web of Science ®Google Scholar
• Dan J, Zhang Y, Peng Z, et al. Postoperative neutrophil-to-lymphocyte ratio change predicts survival of patients with small hepatocellular carcinoma undergoing radiofrequency ablation. PLoS One. 2013;8(3):e58184. doi:10.1371/journal.pone.0058184
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259. doi:10.1158/1078-0432.Ccr-04-0713
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature07205
   PubMed Web of Science ®Google Scholar
• Nagaoka S, Yoshida T, Akiyoshi J, et al. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int. 2007;27(8):1091–1097. doi:10.1111/j.1478-3231.2007.01550.x
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Ikeda Y, Korenaga D, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer. 2005;103(9):1856–1864. doi:10.1002/cncr.20976
   PubMed Web of Science ®Google Scholar
• Yunger S, Bar El A, Zeltzer LA, et al. Tumor-infiltrating lymphocytes from human prostate tumors reveal anti-tumor reactivity and potential for adoptive cell therapy. Oncoimmunology. 2019;8(12):e1672494. doi:10.1080/2162402x.2019.1672494
   PubMed Web of Science ®Google Scholar
• Zhang E, Yang P, Gu J, et al. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. J Hematol Oncol. 2018;11(1):102. doi:10.1186/s13045-018-0646-9
   PubMed Web of Science ®Google Scholar
• Hoffmann TK, Dworacki G, Tsukihiro T, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res. 2002;8(8):2553–2562.
   PubMed Web of Science ®Google Scholar
• Väyrynen JP, Tuomisto A, Klintrup K, Mäkelä J, Karttunen TJ, Mäkinen MJ. Detailed analysis of inflammatory cell infiltration in colorectal cancer. Br J Cancer. 2013;109(7):1839–1847. doi:10.1038/bjc.2013.508
   PubMed Web of Science ®Google Scholar
• Iseda N, Itoh S, Yoshizumi T, et al. Lymphocyte-to-C-reactive protein ratio as a prognostic factor for hepatocellular carcinoma. Int J Clin Oncol. 2021;26(10):1890–1900. doi:10.1007/s10147-021-01985-x
   PubMed Web of Science ®Google Scholar
• Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol. 2018;68(3):526–549. doi:10.1016/j.jhep.2017.09.016
   PubMed Web of Science ®Google Scholar
• Pravisani R, Mocchegiani F, Isola M, et al. Postoperative trends and prognostic values of inflammatory and nutritional biomarkers after liver transplantation for hepatocellular carcinoma. Cancers. 2021;13(3):513. doi:10.3390/cancers13030513
   PubMed Web of Science ®Google Scholar
• Chan JCY, Diakos CI, Chan DLH, et al. A longitudinal investigation of inflammatory markers in colorectal cancer patients perioperatively demonstrates benefit in serial remeasurement. Ann Surg. 2018;267(6):1119–1125. doi:10.1097/sla.0000000000002251
   PubMed Web of Science ®Google Scholar